What is Criterion Edge?
Founded in 2016, Criterion Edge operates at the intersection of clinical science and regulatory compliance. The company provides comprehensive regulatory writing services tailored to the specific needs of the Medical Device, Biopharma, and In-Vitro Diagnostic sectors. By deploying a highly skilled team of medical writers and quality assurance professionals, the firm bridges the gap between complex clinical data and the rigorous documentation requirements mandated by global health authorities. Their market position is defined by a commitment to precision, flexibility, and the ability to manage documentation lifecycles for both emerging start-ups and established multinational corporations.
How much funding has Criterion Edge raised?
Criterion Edge has raised a total of $345K across 2 funding rounds:
Debt
$150K
Debt
$195K
Debt (2020): $150K with participation from PPP
Debt (2021): $195K led by PPP
Key Investors in Criterion Edge
PPP
Public-Private Partnership
What's next for Criterion Edge?
With the recent influx of capital, Criterion Edge is well-positioned to expand its footprint in the global regulatory services market. The strategic focus will likely shift toward enhancing their digital documentation infrastructure and scaling their expert workforce to meet the rising demand for clinical evaluation reports and technical documentation. By investing in advanced quality control systems and expanding their reach into new therapeutic areas, the company aims to further solidify its reputation as a leader in regulatory compliance. This late-stage funding environment provides the necessary runway to pursue long-term market dominance and operational excellence in an increasingly regulated global economy.
See full Criterion Edge company page
